Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

HAJEK

Showing results (1471-1480 of 1,751) with videos related to

Pageof 176
Sort By:
Journal of Affective Disorders|October 11, 2016
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label studyRodrigo B Mansur, Juhie Ahmed, Danielle S Cha, et al.
European Journal of Haematology|April 5, 2017
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS)Hauke Thomsen, Chiara Campo, Niels Weinhold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesityJohn P Pierce, Marcia L Stefanick, Shirley W Flatt, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 29, 2024
Attitudes, knowledge, and risk perceptions of patients who received elective genomic testing as a clinical serviceEmilie S Zoltick, Megan Bell, Madison R Hickingbotham, et al.
Cancer|May 19, 2016
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Aging & Mental Health|March 2, 2026
Activity participation reduces the risk of late-life depression: a sex-specific analysis of the AgeCoDe/AgeQualiDe studyJosefine Kappe, Alexander Pabst, Melanie Luppa, et al.
Leukemia & Lymphoma|November 15, 2011
MyelomA Genetics International ConsortiumGareth Morgan, Hans Erik Johnsen, Hartmut Goldschmidt, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapyPavel Nemec, Zuzana Zemanova, Henrieta Greslikova, et al.
Pageof 176

Showing results (1471-1480 of 1,751) with videos related to

Sort By:
Pageof 176
Journal of Affective Disorders|October 11, 2016
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label studyRodrigo B Mansur, Juhie Ahmed, Danielle S Cha, et al.
European Journal of Haematology|April 5, 2017
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS)Hauke Thomsen, Chiara Campo, Niels Weinhold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesityJohn P Pierce, Marcia L Stefanick, Shirley W Flatt, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 29, 2024
Attitudes, knowledge, and risk perceptions of patients who received elective genomic testing as a clinical serviceEmilie S Zoltick, Megan Bell, Madison R Hickingbotham, et al.
Cancer|May 19, 2016
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Aging & Mental Health|March 2, 2026
Activity participation reduces the risk of late-life depression: a sex-specific analysis of the AgeCoDe/AgeQualiDe studyJosefine Kappe, Alexander Pabst, Melanie Luppa, et al.
Leukemia & Lymphoma|November 15, 2011
MyelomA Genetics International ConsortiumGareth Morgan, Hans Erik Johnsen, Hartmut Goldschmidt, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapyPavel Nemec, Zuzana Zemanova, Henrieta Greslikova, et al.
Pageof 176